Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Bergmann L, Heil G, Kolbe K, et al, "Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia," Leuk Lymphoma , 1995, 16(3-4):271-9. [PubMed 7719235 ] Lange BJ, Smith FO, Feusner J, et al, "Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group," Blood , 2008, 111(3):1044-53. [PubMed 18000167 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Sievers EL, Lange BJ, Sondel PM, et al, “Feasibility, Toxicity, and Biologic Response of Interleukin-2 After Consolidation Chemotherapy for Acute Myelogenous Leukemia: A Report From the Children's Cancer Group,” J Clin Oncol, 1998, 16(3):914-9. [PubMed 9508173 ] Whittington R and Faulds D, “Interleukin-2: A Review of Its Pharmacological Properties and Therapeutic Use in Patients With Cancer,” Drugs , 1993, 46(3):446-514. [PubMed 7693434 ] Topic 13299 Version 37.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]